CO-1002 / Champions Oncology - LARVOL DELTA

Targeting tumor synthetic vulnerabilities and immune evasion mechanisms with CO-1002 (AACR 2023) - "A series of highly potent small molecule compounds were established against these targets using structure-based design, which shows robust in vitro and in vivo target engagement and favorable cytotoxic and phenotypic profiles across a large panel of cancer cell lines and PDXs. Collectively, this therapeutic program shows significant promise in treating a multitude of solid tumors as a monotherapy and in combination with currently approved immune therapies."

IO biomarker • Oncology • Solid Tumor • BRCA